Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australian Patent Amendments To Trade Pact Face Scrutiny From PhRMA, USTR

This article was originally published in The Pink Sheet Daily

Executive Summary

Last-minute changes to the Australian law implementing the free trade deal may violate the underlying agreement and WTO rules on patent rights, PhRMA says. The amendments are designed to block “evergreening” practices by brand name drug makers.

You may also be interested in...

President Bush Signs Australia Free Trade Act

The U.S. pharmaceutical industry has its first formal mechanism to challenge foreign price controls following the signing of the U.S.-Australia free trade agreement by President Bush Aug. 3

Rx Reimportation Ban In Australia Free Trade Deal Questioned By Sen. Grassley

The reimportation issue is still being debated in Congress, Grassley notes. The trade agreement calls for changes to Australia's Pharmaceutical Benefits Scheme, including independent review of product inclusion.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts